Technology
Health
Biotechnology

Rubius Therapeutics

$14.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.43 (-2.85%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell RUBY and other stocks, options, ETFs, and crypto commission-free!

About RUBY

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA.

Employees
142
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
1.20B
Price-Earnings Ratio
Dividend Yield
Average Volume
140.45K
High Today
$15.99
Low Today
$14.52
Open Price
$15.14
Volume
358.98K
52 Week High
$27.73
52 Week Low
$12.71

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
2018 IPO
US
North America

RUBY Earnings

-$3.33
-$2.32
-$1.32
-$0.31
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.